Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable's platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques like CRISPR-Cas9. This extended monitoring period is essential for tracking delayed adverse events, understanding the durability of the therapy, and ensuring the long-term impact on patients – but can add significant hardships.
By embracing a digital, patient-centric approach, Medable's model addresses key gaps in traditional LTFU execution.
Share
CGTs offer transformative potential yet they also require prolonged safety monitoring, often spanning 15 years post-treatment. Traditional models for LTFU impose logistical and financial challenges on participants, contributing to lower participation and high attrition rates over time. According to a 2024 survey conducted by the Emily Whitehead Foundation and Catalyst Healthcare Consulting, 20% of CAR T-cell therapy patients stop participating in long-term follow-up altogether, with 80% of that group ceasing participation at or after five years post-treatment. Distance to sites, lack of awareness about local follow-up options, and burdensome travel are frequently cited as key barriers.
'Long-term follow-up is essential to ensure the durability and safety of advanced therapies, but the current system isn't working for patients or sponsors,' said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. 'With our new LTFU model, we're reimagining how post-treatment data is captured - putting patients at the center while ensuring scientific and regulatory rigor.'
Medable's digital-first LTFU offering includes:
Remote and Hybrid Patient Interaction: Patients can engage in follow-up through flexible virtual, in-person, or blended formats that meet their individual needs and life circumstances.
Seamless Transition from Parent Trials: Integrated workflows and data continuity ensure a frictionless handoff from interventional studies to long-term observational follow-up.
Patient-First Data Capture and Adherence Monitoring: Leveraging mobile technology, patient reported questionnaires and local healthcare providers to track key endpoints and ensure consistent participation over time.
Personalized Patient Communication: Ongoing engagement through tailored content, reminders, and support tools to build trust and maintain long-term connection.
By embracing a digital, patient-centric approach, Medable's model addresses key gaps in traditional LTFU execution – improving retention, increasing diversity, and reducing the long-term cost burden for both sponsors and sites.
Medable Booth # 10105.
About Medable
Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
19 minutes ago
- New York Post
Nationwide recall issued for popular chocolate brand that contains potentially ‘life-threatening' ingredient
A popular chocolate treat is being pulled from shelves nationwide over an ingredient that may trigger severe – and potentially deadly – allergic reactions, federal officials warned. An urgent recall was issued after Lipari Foods discovered that its 14-ounce packages of JLM Branded Dark Chocolate Nonpareils may contain undeclared milk, the US Food and Drug Administration (FDA) announced Friday. Those with milk allergies are urged to avoid consuming the potentially lethal candy. Select packages of JLM Branded Dark Chocolate Nonpareils may contain undeclared milk. USFDA 'People who have allergies to milk run the risk of serious or life-threatening allergic reactions if they consume these products,' the dire bulletin stated. The Michigan-based company initiated the recall after its distributor, Weave Nut Company, alerted them that the candy may contain the dairy allergen, which was not disclosed on the packaging. But the sprinkle-topped chocolate discs, sold in clear plastic tubs, had already made their way to retailers across the country. The recall targets packaging with lot codes 28202501A, 29202501A, 23202504A, 14202505A, 15202505A, and 03202506A on the bottom label. No illnesses or adverse reactions have been reported in connection with the recall. Brent Hofacker – The FDA advised customers to return the product to the place of purchase for a full refund. No illnesses or adverse reactions have been reported in connection with the recall.
Yahoo
2 hours ago
- Yahoo
Check Your Freezer—FDA Announces Potentially Life-Threatening Recall of Popular Ice Cream
Summer is just around the corner and ice cream is the quintessential warm weather treat. But if you have a carton or two chilling in your freezer, you might want to check the label. Breyers recently issued a recall on 6,668 cases of ice cream due to "undeclared allergens and mislabeled product." According to the FDA, the voluntary recall was initiated on June 2 because Breyers Rocky Road, which contains the almonds, was packaged incorrectly. The ice cream was packaged in Breyers Chocolate Truffle tubs with Rocky Road lids, which may be a concern for anyone who purchased the product and has a nut allergy. While almonds are a tree nut, the Chocolate Truffle tubs offer misleading ingredient information. The tubs say "may contain tree nuts" while the lids say "contain almonds." The FDA classified the recall as a Class II, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." So how do you know if your ice cream is affected? Take a peek at the packaging of your Breyers ice cream tub. Affected products have the lot number: JUL1026GB3 and UPC code: 077567457288. In a statement to PEOPLE, Breyers says: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
6 hours ago
- Yahoo
Chocolate Recalled Nationwide Due to Potential 'Life-Threatening Allergic Reaction': Here's What You Need to Know
A nationwide recall has been issued for JLM-brand Dark Chocolate Nonpareils due to a risk of 'serious or life-threatening allergic reaction," per the FDA The recall occurred after it was discovered that batches of the product may contain 'undeclared milk' No illnesses have currently been reported, and consumers who purchased the batches in question are urged to return them to the place of purchaseA nationwide recall has been issued for a common type of chocolate due to 'risk of serious or life-threatening allergic reaction,' according to the U.S. Food & Drug Administration (FDA). Michigan-based Lipari Foods is recalling its 14-ounce packages of JLM Branded 'Dark Chocolate Nonpareils" as they may contain "undeclared milk," per an announcement posted on the FDA's website on Friday, June 20. 'People who have allergies to milk run the risk of serious or life-threatening allergic reaction if they consume these products,' the announcement said. According to the FDA, the Dark Chocolate Nonpareils were distributed nationwide and also come in 14-ounce clear plastic tubs. The tubs in question will be marked with one of the following lot numbers on the label: 28202501A, 29202501A, 23202504A, 14202505A, 15202505A or 03202506A. No illnesses have been reported to date in connection with the recall, per the FDA. The organization additionally said that the recall occurred after Lipari Foods was notified of the error by the Pennsylvania-based Weaver Nut Company, which distributes and manufactures candy and nuts. The FDA is urging customers who have purchased the 14-ounce packages to return them to the place of purchase 'for a full refund.' PEOPLE reached out to Lipari Foods for comment on Saturday, June 21, but did not receive an immediate response. This isn't the first time that a nationwide recall of chocolate has been issued in recent months. In December 2024, Cal Yee Farms' recalled some of its chocolate products due to the fact that they potentially contained 'undeclared milk, soy, wheat, sesame, FD&C #6 and almonds.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. The FDA heightened the risk level of the recall earlier this year in January, after it was discovered that the products may also contain undeclared milk. Read the original article on People
